FDA Expands ANKTIVA Approval to Include Papillary-Only NMIBC
ImmunityBio said the FDA expanded ANKTIVA’s indication to include BCG-unresponsive non-muscle invasive bladder cancer patients with papillary-only tumors.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
FDA Expands ANKTIVA® Approval for BCG — Unresponsive Non — Muscle — Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
For best results when printing this announcement, please click on link below: FDA Expands ANKTIVA(® )Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease Expanded indication extends ANKTIVA plus BCG to patients with BCG-unresponsive non-muscle-invasive bladder cancer